Squamous Cell Carcinoma of Head and Neck: all 1,711 studies

Page 17 of 18. Open to participants first (544), then studies with results posted, then the rest; newest registration first within each.

• Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation TherapyWithdrawnNCT01332279Phase 1
• Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell CancerCompletedNCT01316757Phase 2
• A Trial of Perioperative Immune Enhancing Feed in Patients Undergoing Surgery for Head and Neck CancerCompletedNCT01314755Not applicable
• A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckTerminatedNCT01303237
• Accelerated Fractionation Radiotherapy (AFRT) Versus Concurrent Chemoradiotherapy (Crt) In Locally Advanced Head And Neck Squamous Cell CarcinomaStatus unknownNCT01291095Phase 2
• Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective NeckCompletedNCT01287390Phase 2
• Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological SurgeryCompletedNCT01280318Phase 1/2
• Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck CancerTerminatedNCT01254734Not applicable
• Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck CancerCompletedNCT01254617Phase 1
• Phase 1 and 2 Study of PX-866 and CetuximabCompletedNCT01252628Phase 1/2
• Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV InfectionTerminatedNCT01249443Phase 1
• TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck TumorsTerminatedNCT01245985Phase 2
• Study of PX-866 and Docetaxel in Solid TumorsCompletedNCT01204099Phase 1/2
• Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT01179360
• Efficacy Study of Temsirolimus to Treat Head and Neck CancerCompletedNCT01172769Phase 2
• Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or ChemotherapyTerminatedNCT01164566Not applicable
• L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck CancerCompletedNCT01155609Not applicable
• Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT01154920Phase 2
• An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and NeckTerminatedNCT01142869
• Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET) Insert DeviceWithdrawnNCT01133262
• A Phase 1 Study in Participants With Advanced CancerCompletedNCT01115790Phase 1
• Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT01086826Phase 3
• A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)CompletedNCT01080066
• Human Papillomavirus (HPV) in Squamous Cell Carcinoma of the Head and NeckStatus unknownNCT01079546
• Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell CarcinomaCompletedNCT01064921Phase 1
• A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell CarcinomaCompletedNCT01046266Phase 1
• Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckTerminatedNCT01015664Phase 1/2
• Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus CisplatinStatus unknownNCT00999700Phase 3
• Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration TrialCompletedNCT00995293Phase 3
• Treatment of Advanced Head and Neck CancerTerminatedNCT00982696Phase 2
• Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell CarcinomaCompletedNCT00968435Phase 2
• Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity CancerCompletedNCT00963326
• Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck CancerActive, not recruitingNCT00957086Phase 3
• A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell CarcinomaCompletedNCT00933387Phase 2
• Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckTerminatedNCT00906360Phase 1
• Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell CarcinomaTerminatedNCT00903461Phase 1
• Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck CancerTerminatedNCT00901537Phase 1
• Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck CancerCompletedNCT00899054Phase 1/2
• Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck CancerCompletedNCT00875849Phase 2
• Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell CarcinomaStatus unknownNCT00855881Phase 2
• A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck CancerCompletedNCT00824343Phase 2
• PET Scans in Patients With Head And Neck Cancer Who Are Undergoing 3-Dimensional Conformal Radiation Therapy And Intensity-Modulated Radiation TherapyCompletedNCT00809016Not applicable
• Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)TerminatedNCT00805012Phase 2
• Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT00771641Phase 3
• 2B or Not 2B? Shoulder Function After Level 2B Neck Dissection: A Randomized Controlled StudyCompletedNCT00765791Not applicable
• Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive TractCompletedNCT00765440Phase 3
• Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By SurgeryCompletedNCT00738868Phase 2
• Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT00736619Phase 1
• Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)Status unknownNCT00652613Phase 2
• Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell CarcinomaStatus unknownNCT00634777Not applicable
• Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)WithdrawnNCT00627835Phase 1
• Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid TumorsCompletedNCT00625456Phase 1
• Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT00623558Phase 2
• Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell CarcinomaCompletedNCT00620139
• Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT00611754Phase 2
• Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbituxCompletedNCT00609284Phase 3
• Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell CarcinomaCompletedNCT00596219Not applicable
• Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and NeckCompletedNCT00513383Phase 1
• Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial CancerTerminatedNCT00499733Early Phase 1
• DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCCCompletedNCT00496652Phase 3
• Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell CancerActive, not recruitingNCT00494182Phase 2
• Dendritic Cell Vaccine for Head and Neck CancerWithdrawnNCT00492947Phase 1
• Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and NeckCompletedNCT00474825Phase 1
• Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck CancerCompletedNCT00470496Phase 1
• Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck CancerCompletedNCT00458978Phase 2
• Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and NeckCompletedNCT00442455Phase 3
• MRX, Radiation, and Chemotherapy for Patients With Resected Squamous Cell Carcinoma of the Head and NeckTerminatedNCT00427102Phase 1
• Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck CancerTerminatedNCT00412776Phase 2/3
• C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT00402545Phase 1
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous TumorTerminatedNCT00377247Phase 1
• A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and NeckCompletedNCT00358930Phase 2
• Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)CompletedNCT00357149Phase 2
• Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and NeckCompletedNCT00318890Phase 1/2
• Study of Proxinium for Treating Patients With Squamous Cell Head and Neck CancerTerminatedNCT00272181Phase 2
• Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)CompletedNCT00268671Phase 1/2
• 0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and NeckCompletedNCT00257738Phase 1
• Study of Unilateral Neck Irradiation in Patients With SCC of the Head and NeckCompletedNCT00206752Not applicable
• Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)CompletedNCT00206219Phase 3
• Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma PatientsCompletedNCT00201383Phase 3
• Chemoprevention Study of Oral Cavity Squamous Cell CarcinomaCompletedNCT00201279Phase 3
• TRACE: Tirapazamine-Radiation And Cisplatin EvaluationCompletedNCT00174837Phase 3
• Very Intense Radiotherapy-chemotherapy Regimen in Advanced HNSCCCompletedNCT00162708Phase 2/3
• Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT00139269Phase 1/2
• Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and NeckCompletedNCT00139243Phase 1/2
• Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck CancerCompletedNCT00114283Phase 2
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
• Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00098631Phase 2
• S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00096512Phase 2
• S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck CancerWithdrawnNCT00095641Phase 2
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
• Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckCompletedNCT00083057Phase 1
• Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and NeckTerminatedNCT00081211Phase 1
• Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT00079053Phase 1
• Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)TerminatedNCT00073450Phase 2
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
• Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckCompletedNCT00063895Phase 1/2
• Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00055913Phase 1/2
• Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck CancerCompletedNCT00055770Phase 1/2
• Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck CancerCompletedNCT00049283Phase 1

← Squamous Cell Carcinoma of Head and Neck overview